No price history available.
Key financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | TWDm | 1,065 | 1,289 | 1,245 | 1,301 | 1,486 | 1,584 | N/A | N/A |
| Operating profit | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | TWDm | 171 | 164 | 162 | 169 | 173 | 181 | N/A | N/A |
| EPS reported | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Maywufa Company Ltd. manufactures and sells hair and skin care products under the Maywufa brand in Taiwan. The company engages in the manufacturing, processing, and distribution of hairdressing products, soap, and cosmetics; distribution, wholesale, and retail trading of various beauty products, health products, and sports equipment; retail and wholesale business of health food, such as vitamin pills and oral liquid nutrients; trading, wholesale, and retail of medical drugs and medical equipment; wholesale and retail sales of food, baby products, and general food products; and wholesale trading and agency business. It also provides consulting and analysis; warehousing services; and mother and baby skin care products under the Mustela brand. In addition, the company provides pharmaceuticals and medical devices, such as PG2 Lyophilized injection for treatment of cancer-related fatigue; AmCad-UT Detection device, an ultrasound CAD for thyroid cancer detection; Bio-Three tablets for the treatment of mild diarrhea, abdominal pain, and constipation; and Cerebrolysin, a supplementary nutrient boost for patients who cannot ingest adequate food and patients who have difficulties in the digestion, absorption, synthesis, and utilization of proteins, as well as for patients suffering from severe trauma, burns, fractures, insufficient protein intake, or malnutrition. Maywufa Company Ltd. was incorporated in 1976 and is headquartered in Taipei, Taiwan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Maywufa Company Ltd. (1731.TW)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Maywufa Company Ltd. manufactures and sells hair and skin care products under the Maywufa brand in Taiwan. The company engages in the manufacturing, processing, and distribution of hairdressing products, soap, and cosmetics; distribution, wholesale, and retail trading of various beauty products, health products, and sports equipment; retail and wholesale business of health food, such as vitamin pills and oral liquid nutrients; trading, wholesale, and retail of medical drugs and medical equipment; wholesale and retail sales of food, baby products, and general food products; and wholesale trading and agency business. It also provides consulting and analysis; warehousing services; and mother and baby skin care products under the Mustela brand. In addition, the company provides pharmaceuticals and medical devices, such as PG2 Lyophilized injection for treatment of cancer-related fatigue; AmCad-UT Detection device, an ultrasound CAD for thyroid cancer detection; Bio-Three tablets for the treatment of mild diarrhea, abdominal pain, and constipation; and Cerebrolysin, a supplementary nutrient boost for patients who cannot ingest adequate food and patients who have difficulties in the digestion, absorption, synthesis, and utilization of proteins, as well as for patients suffering from severe trauma, burns, fractures, insufficient protein intake, or malnutrition. Maywufa Company Ltd. was incorporated in 1976 and is headquartered in Taipei, Taiwan.